Use of Rasagiline or Selegiline and Hospitalizations among Patients with Parkinson's Disease

被引：0
|
作者：
Grubb, Elizabeth [1 ]
Lage, Maureen [2 ]
Castelli-Haley, Jane [1 ]
机构：
[1] Teva Pharmaceut, Kansas City, MO USA
[2] HealthMetr Outcomes Res, Groton, CT USA
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P06087
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Spotlight on Rasagiline in Parkinson’s Disease
    Vicki Oldfield
    Gillian M. Keating
    Caroline M. Perry
    CNS Drugs, 2008, 22 : 83 - 86
  • [32] Effects of Rasagiline on Olfactory Function in Patients With Parkinson's Disease
    Haehner, Antje
    Hummel, Thomas
    Wolz, Martin
    Klingelhoefer, Lisa
    Fauser, Mareike
    Storch, Alexander
    Reichmann, Heinz
    MOVEMENT DISORDERS, 2013, 28 (14) : 2023 - 2027
  • [33] Spotlight on rasagiline in Parkinson's disease
    Oldfield, Vicki
    Keating, Gillian M.
    Perry, Caroline M.
    CNS DRUGS, 2008, 22 (01) : 83 - 86
  • [34] Selegiline reduces daytime sleepiness in patients with Parkinson's disease
    Gallazzi, Marco
    Mauri, Marco
    Bianchi, Maria Laura
    Riboldazzi, Giulio
    Princiotta Cariddi, Lucia
    Carimati, Federico
    Rebecchi, Valentina
    Versino, Maurizio
    BRAIN AND BEHAVIOR, 2021, 11 (05):
  • [35] Treatment of Mild Camptocormia with Selegiline in Patients with Parkinson's Disease
    Yoritaka, Asako
    Mori, Hideo
    Hattori, Nobutaka
    EUROPEAN NEUROLOGY, 2016, 76 (1-2) : 35 - 39
  • [36] Selegiline, pregnancy, and Parkinson's disease
    Kupsch, A
    Oertel, WH
    MOVEMENT DISORDERS, 1998, 13 (01) : 175 - 176
  • [37] Cardiovascular evaluation in Parkinson's disease patients treated with selegiline
    Vanacore, NN
    Giovani, AA
    Di Rezze, SS
    Bonifatri, VV
    Mastrocola, CC
    Meco, GG
    MOVEMENT DISORDERS, 2002, 17 : S97 - S97
  • [38] Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease
    Szoeko, Eva
    Tabi, Tamas
    Riederer, Peter
    Vecsei, Laszlo
    Magyar, Kalman
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (11) : 1735 - 1749
  • [39] Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease
    Éva Szökő
    Tamás Tábi
    Peter Riederer
    László Vécsei
    Kálmán Magyar
    Journal of Neural Transmission, 2018, 125 : 1735 - 1749
  • [40] Selegiline and mortality in Parkinson's disease
    Olanow, CW
    Fahn, S
    Langston, JW
    Godbold, J
    ANNALS OF NEUROLOGY, 1996, 40 (06) : 841 - 845
12345